Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.

Eukaryotic elongation factor 2 kinase (eEF-2K), through its phosphorylation of elongation factor 2 (eEF2), provides a mechanism by which cells can control the rate of the elongation phase of protein synthesis. The activity of eEF-2K is increased in rapidly proliferating malignant cells, is inhibited...

Full description

Bibliographic Details
Main Authors: Ibrahim Tekedereli, S Neslihan Alpay, Clint D J Tavares, Zehra E Cobanoglu, Tamer S Kaoud, Ibrahim Sahin, Anil K Sood, Gabriel Lopez-Berestein, Kevin N Dalby, Bulent Ozpolat
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3401164?pdf=render

Internet

http://europepmc.org/articles/PMC3401164?pdf=render

Similar Items